| answer text |
<p>The patients with clinically actionable reports from the pilot phase are from rare
diseases where improved knowledge of the causal mutation improves the management of
the patient, their family members and possible future reproductive decisions. The
patients diagnosed by whole genome sequencing had not been diagnosed using existing
National Health Service panel tests. We are still evaluating the data from the 100,000
Genomes project to identify options for panel testing or other clinical sequencing
strategies.</p><p> </p>
|
 |
